Neurobehavioral Disorders
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Neurobehavioral Disorders
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Neurocognitive Disorders
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Neurobehavioral Disorders
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Neurobehavioral Disorders
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Pain
Researchers sought to examine the relationship between depressive symptoms and pain in U.S. veterans 50 years of age or older.
Sleep Disorders
Cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder.
Neurobehavioral Disorders
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
